Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: J Thromb Haemost. 2016 Oct 5;14(11):2261–2273. doi: 10.1111/jth.13477

Figure 5.

Figure 5

PolyP-mediated expression of cyclin D1 in EA.hy926 endothelial cells transfected with siRNAs for RAGE and/or P2Y1 or treated with recombinant soluble RAGE (sRAGE). (A) Cells were transiently transfected with control siRNA or siRNA specific for either RAGE or P2Y1 followed by stimulating cells with polyP-70 (25 µM) and monitoring the expression of cyclin D1. Lane 1, RAGE siRNA alone; lane 2, RAGE siRNA + polyP-70; lane 3, P2Y1 siRNA alone; lane 4, P2Y1 siRNA + polyP-70; lane 5, control siRNA alone; lane 6, control siRNA + polyp-70; lane 7, control (no siRNA, buffer only); lane 8, control + polyP-70; lane 9, RAGE and P2Y1 siRNAs alone combined; lane 10, RAGE and P2Y1 siRNAs combined + polyP-70. (B) Analysis of expression of cyclin D1 treated with sRAGE (2.5 µM). Lane 1, sRAGE alone; lane 2, sRAGE + polyP-70; lane 3, control (buffer only); lane 4, control + polyP-70. The efficiency of gene knockdown was >75% in all cases. The results are shown as mean ± standard deviation of 3 different experiments. *P<0.05 for lane 4 (P2Y1 siRNA + polyP), compared to control siRNA + polyP-70 in panel A.